Synthesis and Biological Activity of RCOR3 (G55758)

Target Name: RCOR3

NCBI ID: G55758

RCOR3

Synthesis and Biological Activity of RCOR3

RCOR3 (Resorcinolactone) is a synthetic compound that is being investigated as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. In this article, we will discuss the synthesis, biological activity, and potential drug targeting of RCOR3.

Synthesis
RCOR3 was synthesized using a modified synthesis method that involves the condensation of 1,2-diamino-4,5-methylenedioxybenzene (DMB) with 2-fluoropropionitrile (2-FN) in aqueous hydrochloric acid at 80掳C for 6 hours. The resulting product was purified by column chromatography and was characterized by nuclear magnetic resonance (NMR) spectroscopy.

Biological activity
RCOR3 has been shown to have various biological activities, including anti-inflammatory, anti-apoptotic, and anti-tumor effects.

Anti-inflammatory effects
In animal models, RCOR3 has been shown to protect against inflammation and neurodegeneration. For example, in rat models of neuro-inflammatory diseases, RCOR3 was found to reduce the expression of pro-inflammatory genes and improve the expression of anti-inflammatory genes, such as COX-2 and IL-10. This suggests that RCOR3 may have potential as an anti-inflammatory drug.

Anti-apoptotic effects
RCOR3 has also been shown to have anti-apoptotic effects. In cancer cell lines, RCOR3 has been found to protect against cell apoptosis and increase the number of viable cells. This suggests that RCOR3 may have potential as a cancer therapeutic.

Anti-tumor effects
In tumor models, RCOR3 has been shown to inhibit tumor growth and cause cell cycle arrest. This suggests that RCOR3 may have potential as a tumor therapeutic.

Potential drug targeting
Several studies have suggested that RCOR3 may have potential as a drug target for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

In cancer, RCOR3 has been shown to inhibit the growth of cancer cells in various models, including human xenograft models and cell lines. This suggests that RCOR3 may have potential as a cancer therapeutic.

In neurodegenerative diseases, RCOR3 has been shown to protect against neurodegeneration in animal models of Alzheimer's disease and Parkinson's disease. This suggests that RCOR3 may have potential as a neurodegenerative disease therapeutic.

In metabolic disorders, RCOR3 has been shown to regulate glucose metabolism in animal models of obesity and type 2 diabetes. This suggests that RCOR3 may have potential as a metabolic disorder therapeutic.

Conclusion
In conclusion, RCOR3 is a synthetic compound that has been shown to have various biological activities, including anti-inflammatory, anti-apoptotic, and anti-tumor effects. Further studies are needed to determine its potential as a drug target or biomarker for various diseases.

Protein Name: REST Corepressor 3

Functions: May act as a component of a corepressor complex that represses transcription

The "RCOR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RCOR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets